We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Fireside Chat with Theranos Whistleblowers

By AACC
Posted on 12 Jul 2022
Print article
Image: Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz (Photo courtesy of aacc.org)
Image: Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz (Photo courtesy of aacc.org)
Tuesday, July 26
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center


Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.

After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.

Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.

Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.